Cytokine related treatments of disease
US6423695B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 20, 1999 |
| Grant date | Jul 23, 2002 |
| Priority date | — |
| Expiry date | Dec 20, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/675
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Nucleosides and other compounds to selectively modulate Th1 and Th2 responses relative to each other in the treatment of disease. In one aspect of the invention, administration of a nucleoside or other compound reduces the dosage at which a primary drug is administered. In another aspect of the invention, an abnormality reflected in increased response in one group of cytokines is treated by administering a nucleoside or other compound that increases response in another group of cytokines. In yet another aspect of the invention, a patient is prophylactically treated by administering a nucleoside or other compound that selectively reduces Th1 activity without significantly reducing Th2 activity. In yet another aspect of the invention, a nucleoside or other compound is administered to a patient at a dose that reduces the patient's GTP pool to a degree that selectively reduces one of the Th1 or Th2 responses without significantly reducing the other response. Controlled release dosage forms are particularly contemplated to achieve that result.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.